Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes

HIV Clinical Trials

Volumn 4, Issue 6, 2003, Pages 372-381

  Gallego, Oscar ^a   de Mendoza, Carmen ^a   Labarga, Pablo ^b   Altisent, Carmen ^c   González, Juan ^d   García Alcalde, Isabel ^e   Valer, Luisa ^a   Valencia, Eulalia ^a   Soriano, Vincent ^a,f  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL SAN PEDRO   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL DE CABUEÑES   (Spain)

^f NONE   (Spain)

Author keywords

Drug resistance; HIV; Multinucleoside resistance; Protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; GENE DELETION; GENE INSERTION; GENETIC ANALYSIS; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANCE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; VIREMIA; VIRUS LOAD; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SALVAGE THERAPY; SURVIVORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0344465949     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/X618-KWKJ-WCTQ-LQ2L     Document Type: Article

References (36)

1. Mouton Y, Alfandri S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS. 1997;11:F101-F105.
2. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med. 1998;338:853-860.
3. Wit F, van Leeuwen G, Weverling S, et al. Outcome and predictors of failure of HAART: one-year follow-up of a cohort of HIV-1 infected persons. J Infect Dis. 1999;179:790-798.
4. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS. 2001;15:1894-1896.
5. Hirsch M, Brun-Vèzinet F, D'Aquila R, et al. Antiretroviral drug resistance testing in adults with HIV-1 infection. JAMA. 2000;283:2417-2426.
6. Shafer R, Iversen A, Winters M, et al. Drug resistance and heterogeneous long-term virologic responses of HIV type-1 infected subjects to zidovudine and didanosine combination therapy. J Infect Dis. 1995;172:70-78.
7. Shafer R, Winters M, Palmer S, et al. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med. 1998;128:906-911.
8. International AIDS Society-USA Resistance Testing Panel and HIV InSite. Antiretroviral resistance mutations. HIV Clin Trials. 2001;2(4):346-355.
9. Meyer P, Matsuura S, So A, Scott W. Unblocking of chain-terminated primer by HIV-1 RT through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA. 1998;95:13471-13476.
10. De Mendoza C, Gallego O, Soriano V. Mechanisms of drug resistance to antiretroviral drugs - clinical implications. AIDS Rev. 2002;4:64-82.
11. Schmit J, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV type 1 patient strain. J Infect Dis. 1996;174:962-928.
12. Schmit J, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS. 1998;12:2007-2015.
13. Shirasaka T, Kavlick M, Ueno T, et al. Emergence of HIV type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA. 1995;92:2398-2402.
14. Villalba N, Gómez-Cano M, Holguín A, et al. Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues. Eur J Clin Microbiol Infect Dis. 1999;18:372-375.
15. Larder B, Bloor S, Kemp S, et al. A family of insertion mutations between codons 67 and 70 of HIV type 1 reverse transcriptase confer multi-nucleoside analog resistance. Antivir Agents Chemother. 1999;43:1961-1967.
16. Ross L, Johnson M, Graham N, et al. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1 infected individuals, including those without prior or concurrent zidovudine therapy. J Hum Virol. 1999;2:290-295.
17. Briones C, Mas A, Pérez-Olmeda M, Altisent C, Domingo E, Soriano V. Prevalence and genetic heterogeneity of the RT T69S-S-X insertion in pretreated HIV-infected patients. Intervirology. 2001;44:339-343.
18. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of HIV type 1 variants with insertions or deletions in the RT: multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother. 2001;45:1836-1842.
19. Verhosfstede C, Fransen K, Marissens D, et al. Isolation of HIV-RNA from plasma: evaluation of eight different extraction methods. J Virol Methods. 1996;60:155-159.
20. Rodríguez-Rosado R, Soriano V, Dona C, et al. Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antiviral Ther. 1999;4:229-231.
21. Gómez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998;12:1015-1020.
22. Balotta C, Violin M, Monno L, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1 infected Italian patients with virological failure. J Acquir Immune Defic Syndr. 2000;24:232-240.
23. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristic of multinucleoside-resistant HIV type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother. 2000;44:2109-2117.
24. Kavlick M, Wyvill K, Yarchoan R, Mitsuya H. Emergence of multi-dideoxynucleoside-resistant HIV-1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis. 1998;98:1506-1513.
25. Winters M, Coolley K, Cheng P, et al. Genotypic, phenotypic, and modeling studies of a deletion in the β3-β4 region of the HIV type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol. 2000;74:10707-10713.
26. Imamichi T, Sinha T, Imamichi H, et al. High-level resistance to 3′-azido-3′-deoxythimidine due to a deletion in the reverse transcriptase gene of HIV type 1. J Virol. 2000;74:1023-1028.
27. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.hivatis.org
28. Piketty C, Castiel P, Belec L, et al. Discrepant response to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-750.
29. Hogg R, Havlir D, Miller V, Montaner J. To stop or not to stop: that is the question, but what is the answer? AIDS. 2002;16:787-789.
30. García-Lerma G, Gerrish P, Wright A, Qari S, Heneine W. Evidence of a role for the Q151L mutation and the viral background in the development of multiple dideoxynucleoside-resistant HIV-1. J Virol. 2000;74:9339-9346.
31. Maggiolo F, Callegaro A, Gregis G, et al. Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses. AIDS. 2002;16:298-299.
32. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS. 2002;16:245-249.
33. Phenix B, Mandy F, Kravcik S, et al. Decreased HIV-associated apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 2000;16:559-567.
34. Stoddart C, Mammano F, Linquist-Stepps V, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nature Med. 2001;7:712-718.
35. Belec L, Si-Mohamed A, Goujon C, et al. High levels of drug-resistant HIV variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis. 2000;181:1808-1812.
36. Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4+ cell counts in HIV-Infected patients receiving a protease inhibitor containing antiretroviral regimen. J Infect Dis. 2002;185:471-480.